Stem Cell Clinic

Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors

By Global News Feed

MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya’s board. Mr. Mendel has served as a member of Akoya’s board of directors since June 2021 and has over 30 years of financial and operational management experience.

See the original post:
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2024 it awarded inducement grants to nine new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

More:
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Helio Genomics Methylation Model Score for Early Cancer Detection Awarded as a Top Abstract for the 2024 San Antonio Liver Cancer Symposium

By Global News Feed

IRVINE, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced that its abstract entitled “Cell-free DNA methylation biomarkers for evaluating prognosis and treatment response in patients with hepatocellular carcinoma”, was selected as one of the top three abstracts, and as a poster presentation, at the 2024 San Antonio Liver Cancer Symposium, to be held at the Hilton Palacio del Rio in San Antonio, Texas from October 11–12, 2024. This study was conducted in collaboration with Ochsner Health.

Original post:
Helio Genomics Methylation Model Score for Early Cancer Detection Awarded as a Top Abstract for the 2024 San Antonio Liver Cancer Symposium

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

By Global News Feed

CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter and review recent corporate developments.

The rest is here:
Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million…

By Global News Feed

CINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please note that in the first paragraph of the release, the name of the financial advisor to Onconetix in the transaction had been corrected to Tungsten Advisors. The corrected release follows.

The rest is here:
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

By Global News Feed

Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

Continue reading here:
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

By Global News Feed

Daix (France), Long Island City (New York, United States), September 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today provided a corporate and a financial update for the six months ended June 30, 2024.

Read the original here:
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

→←